ORNBVH Stock Overview Develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Orion Oyj Historical stock prices Current Share Price €44.90 52 Week High €49.89 52 Week Low €38.99 Beta 0.35 1 Month Change 1.14% 3 Month Change -3.25% 1 Year Change n/a 3 Year Change 25.74% 5 Year Change 8.06% Change since IPO 194.43%
Recent News & Updates Orion Corporation Announces Change in Group Executive Management Board Dec 20
Orion Oyj Updates Earnings Guidance for the Full Year 2024 Oct 29
Orion Corporation Decides to Terminate the ODM-111 Development Program Oct 25
Orion Oyj, Annual General Meeting, Apr 03, 2025 Aug 09 Orion Oyj to Report First Half, 2025 Results on Jul 18, 2025
Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint Jul 17 See more updates Orion Corporation Announces Change in Group Executive Management Board Dec 20
Orion Oyj Updates Earnings Guidance for the Full Year 2024 Oct 29
Orion Corporation Decides to Terminate the ODM-111 Development Program Oct 25
Orion Oyj, Annual General Meeting, Apr 03, 2025 Aug 09 Orion Oyj to Report First Half, 2025 Results on Jul 18, 2025
Orion Announces Phase III Aranote Trial of Darolutamide in Combination with Androgen Deprivation Therapy in Men with Metastatic Hormone-Sensitive Prostate Cancer Meets Primary Endpoint Jul 17
Orion Oyj Revises Earnings Guidance for the Year 2024 Jul 02
Orion Corporation Announces Change in Orion Group Executive Management Board as of 31 May 2025 May 08 Orion Corporation Announces Appointments to Nomination Committee
Orion Corporation Announces Change in Executive Management Board, Effect as of 1 April 2024 Mar 22 Orion Corporation Announces Board and Committee Appointment Orion Oyj Announces Retirement of Mikael Silvennoinen as Board Member
Orion Oyj Announces CFO Changes Jan 23
Orion Corporation Announces Phase 3 Clinical Trials with ODM-208 (MK-5684) posted to ClinicalTrials.gov Database Nov 22
Orion Corporation Receives Fda Approval for Bonqat (Pregabalin Oral Solution) Nov 21
Orion Group Appoints Julia Macharey as Senior Vice President, People & Cultur Aug 23 Orion Oyj to Report First Half, 2024 Results on Jul 18, 2024
Second quarter 2023 earnings released Jul 18 Orion Oyj Announces Resignation of Jari Karlson as Chief Financial Officer
First quarter 2023 earnings released Apr 28
Upcoming dividend of €1.60 per share at 3.7% yield Mar 16
Insider recently sold €233k worth of stock Feb 28
Full year 2022 earnings released: EPS: €2.49 (vs €1.38 in FY 2021) Feb 11 Orion Oyj Provides Earnings Guidance for the Year 2023
Orion Oyj Announces Positive CHMP Opinion for Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer Jan 28
Orion Group Provides Earnings Guidance for the Full Year 2022 Oct 21 Orion Group Appoints Liisa Hurme as CEO, Effective 1 January 2023
Orion Oyj Announces Executive Changes Sep 21
Orion Announces Approval of Additional Indication of Darolutamide in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (Mhspc) from U.S. FDA Aug 09
Second quarter 2022 earnings released Jul 16 Orion Oyj to Report Nine Months, 2023 Results on Oct 26, 2023
Orion Oyj to Report Q1, 2023 Results on Apr 27, 2023 Jul 15
Orion Oyj Revises Earnings Guidance for the Full Year 2022 Jul 13
Orion Oyj to Report Q2, 2022 Results on Jul 15, 2022 Jun 29
Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a. from Inovet Bv for €130 million. Jun 17
Orion Oyj (HLSE : ORNBV) acquired V.M.D. n.v./s.a.from Inovet Bv for €130 million. Jun 16
Orion Oyj Announces Executive Changes May 02
First quarter 2022 earnings released Apr 29 Orion Oyj Appoints Liisa Hurme as President and the Chair of the Executive Management Board, as of 1 November 2022
Upcoming dividend of €1.50 per share Mar 17
Orion’S Collaboration Partner Bayer Submits Applications in the U.S. and Eu for Additional Indication of Darolutamide Mar 10
Investor sentiment improved over the past week Feb 19
Orion Corporation Announces Results from an Ongoing Phase I/II CYPIDES Trial of ODM-208 Present at ASCO-GU Feb 19
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 11 Orion Oyj Provides Earnings Outlook for the Year 2022
Orion Announces Arasens Trial with Darolutamide in Combination with Docetaxel and Androgen Deprivation Therapy Meets Primary Endpoint of Significantly Increasing Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer Dec 03
Third quarter 2021 earnings released Oct 21
Second quarter 2021 earnings released: EPS €0.40 (vs €0.54 in 2Q 2020) Jul 20
Orion Oyj Provides Earnings Guidance for the Year 2021 Jul 20
Orion Oyj Recalls Multivita Forte Dietary Supplement from Consumers Jul 14
Orion Animal Health’s Tessie® (tasipimidine) Receives Positive CVMP Opinion Jun 22
Orion Corporation’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy Jun 10
Orion Animal Health’s Bonqat® (Pregabalin) Receives Positive CVMP Opinion May 19
First quarter 2021 earnings released: EPS €0.42 (vs €0.48 in 1Q 2020) Apr 29
Orion Oyj Provides Earnings Guidance for the Year 2021 Apr 28
Upcoming Dividend of €1.50 Per Share Mar 19
Revenue misses expectations Mar 05
Full year 2020 earnings released: EPS €1.57 (vs €1.43 in FY 2019) Mar 05
New 90-day low: €34.16 Mar 02
Full year 2020 earnings released: EPS €1.57 (vs €1.43 in FY 2019) Feb 11
Revenue misses expectations Feb 11
New 90-day low: €35.69 Feb 10
Tenax Therapeutics, Inc. Enters into Amendment to License Agreement with Orion Corporation Oct 16
Orion Is Planning to Renew Its R&D Strategy and Organisation Sep 11 Orion Oyj to Report First Half, 2021 Results on Jul 19, 2021 Shareholder Returns ORNBVH GB Pharmaceuticals GB Market 7D 0% -2.5% -2.6% 1Y n/a -3.8% 2.7%
See full shareholder returns
Return vs Market: Insufficient data to determine how ORNBVH performed against the UK Market .
Price Volatility Is ORNBVH's price volatile compared to industry and market? ORNBVH volatility ORNBVH Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: ORNBVH's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine ORNBVH's volatility change over the past year.
About the Company Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
Show more Orion Oyj Fundamentals Summary How do Orion Oyj's earnings and revenue compare to its market cap? ORNBVH fundamental statistics Market cap €6.05b Earnings (TTM ) €331.70m Revenue (TTM ) €1.43b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ORNBVH income statement (TTM ) Revenue €1.43b Cost of Revenue €573.20m Gross Profit €856.00m Other Expenses €524.30m Earnings €331.70m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
Earnings per share (EPS) 2.36 Gross Margin 59.89% Net Profit Margin 23.21% Debt/Equity Ratio 27.8%
How did ORNBVH perform over the long term?
See historical performance and comparison Dividends
3.8% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/19 05:23 End of Day Share Price 2024/12/04 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Orion Oyj is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Peter Ankersen ABG Sundal Collier Graham Glyn Parry BofA Global Research Kristofer Liljeberg-Svensson Carnegie Investment Bank AB
Show 15 more analysts 
